ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 3163

The Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients

Uyen Sa D.T. Nguyen1, Yuqing Zhang2, Na Lu3, Qiong Louie-Gao4, Jingbo Niu5, David T. Felson5, Michael P. Lavalley6, Thorvardur Love7,8, Maureen Dubreuil4, Jeffrey A. Sparks9, Elizabeth W. Karlson10 and Hyon K. Choi3, 1Orthopedics & Physical Rehabilation, Univerity of Massachusetts Medical School, Worcester, MA, 2Clinical Epidemilogy and Training Unit, Boston University School of Medicine, Boston, MA, 3Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 4Boston University School of Medicine, Boston, MA, 5Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 6Biostatistics, Boston University, Boston, MA, 7Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 8Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 9Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, 10Rheumatology, Brigham & Women's Hospital, Boston, MA

Meeting: ACR/ARHP Annual Meeting 2015

Date of first publication: September 29, 2015

Keywords: Epidemiologic methods, psoriasis and psoriatic arthritis

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Epidemiology and Public Health IV: Risk Factors and Comorbidities for SLE and Psoriatic Arthritis

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Smoking is a strong risk factor of psoriasis,
but a previous study has suggested that
smoking protects
against the development of psoriatic
arthritis (PsA) among psoriasis (PsO) patients.  These paradoxical findings
occur because of two possibilities.  First, a type of selection bias called
index event bias arises from selecting a group of patients (e.g. PsO) on the
causal pathway (e.g., between smoking and PsA).  Second, the causal net effect
(i.e., total effect) of
smoking cannot be validly estimated using conventional methods (Figure a).
We sought to evaluate the impact of smoking on the risk of PsA among PsO
patients (index population)
, and clarify the paradox using a counterfactual
mediation analysis.

Methods: We used 1995-2015 data from The
Health Improvement Network (THIN), an electronic medical records database
representative of the UK general population. We analyzed data from adults (age
≥ 20 years), free of PsO and PsA after at least 1 year of enrollment into
the THIN database, and with available data on factors of interest. Follow-up
began with first record of smoking status (exposure) after the 1-year
enrollment period and ended at time of PsA diagnosis, death, disenrollment
in THIN, or the end of the study period, whichever
came first. Using Cox regression, we assessed the effect of smoking on incident
PsA in the general population, and restricting on incident PsO patients. We
then clarified the paradox using marginal structural models (MSM) for mediation
analysis to partition the total effect of smoking on PsA into its indirect
effect
(via its effect on PsO) and its direct
effect
not through PsO.
All analyses were
adjusted for known confounders. 

Results: There were ~3.7 million
subjects without PsO and PsA at baseline (mean age 47 years; 54% females; 27%
current smokers, and 20% ex-smokers). Of those, 46,372 developed incident PsO
of which 715 developed incident PsA.  The adjusted hazard ratio (HR) for smoking
and the risk of PsA among PsO patients was 0.85 (95%CI: 0.70, 1.04), but the
corresponding HR for PsA in the general THIN population was 1.19 (95%CI: 1.06,
1.33) (Table).  Using MSM, the indirect effect of current smoking
compared with non-smoking on risk of PsA was 1.20 (95%CI: 1.12, 1.28); the direct
effect
was 0.99 (95%CI: 0.92, 1.06) and the total effect was 1.19
(95%CI: 1.06, 1.33) (Table). 

Conclusion:  We showed that
conditioning on PsO can reverse the association between smoking and PsA, and
that the effect of smoking on the risk of PsA may be mediated almost entirely
through smoking’s effect on PsO.  Conditioning on an index event may bias
conclusions about the contribution of modifiable risk factors; therefore
investigators should consider study designs that are free of such bias (Figure b, analysis assessing the impact
of exposure status change or analogous randomized trials in the index
population).  


Disclosure: U. S. D. T. Nguyen, None; Y. Zhang, None; N. Lu, None; Q. Louie-Gao, None; J. Niu, None; D. T. Felson, None; M. P. Lavalley, None; T. Love, None; M. Dubreuil, None; J. A. Sparks, None; E. W. Karlson, None; H. K. Choi, None.

To cite this abstract in AMA style:

Nguyen USDT, Zhang Y, Lu N, Louie-Gao Q, Niu J, Felson DT, Lavalley MP, Love T, Dubreuil M, Sparks JA, Karlson EW, Choi HK. The Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-smoking-paradox-in-the-development-of-psoriatic-arthritis-among-psoriasis-patients/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2015

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-smoking-paradox-in-the-development-of-psoriatic-arthritis-among-psoriasis-patients/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology